Malin (MLLNF) Additional Paid-In Capital: $3.31 Mil(As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLLNF Malin Corporation PLC MLLNF
17 GF Score
Price $6.40
View Full Analysis

What is Malin Additional Paid-In Capital?

Malin MLLNF 17 Additional Paid-In Capital is $3.31 Mil as of Dec. 2024. GuruFocus rates MLLNF with a GF Score™ of 17/100.


Malin's quarterly additional paid-in capital declined from Dec. 2023 ($125.05 Mil) to Jun. 2024 ($121.32 Mil) but then stayed the same from Jun. 2024 ($121.32 Mil) to Dec. 2024 ($3.31 Mil).

Malin's annual additional paid-in capital increased from Dec. 2022 ($120.49 Mil) to Dec. 2023 ($125.05 Mil) but then declined from Dec. 2023 ($125.05 Mil) to Dec. 2024 ($3.31 Mil).

Malin Additional Paid-In Capital Related Terms

Malin Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Malin's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Malin Additional Paid-In Capital Chart

Malin Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 138.14 128.39 120.49 125.05 3.31

Malin Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 120.49 123.06 125.05 121.32 3.31
MLLNF
17GF Score
Malin Corporation PLC MLLNF
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Malin Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $3.31 Mil mean?
Malin (MLLNF) has a Additional Paid-In Capital of $3.31 Mil as of Dec. 2024. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Malin and its competitors.
Is Malin's Additional Paid-In Capital too high?
Malin's current Additional Paid-In Capital is $3.31 Mil. Overall, Malin has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Malin's Additional Paid-In Capital compare to ZTS and UTHR?
Malin's Additional Paid-In Capital of $3.31 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Drug Manufacturers company?
A good Additional Paid-In Capital depends on the Drug Manufacturers industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Malin and its competitors. Malin's current Additional Paid-In Capital is $3.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malin stock overvalued right now?
Malin (MLLNF) has a current Additional Paid-In Capital of $3.31 Mil. The current Additional Paid-In Capital is $3.31 Mil. Malin's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Malin (MLLNF), the current Additional Paid-In Capital is $3.31 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Malin Business Description

Address 50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02
Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.
17GF Score

Get the complete analysis for MLLNF

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.40
Price